XTL Biopharmaceuticals Ltd.

Regulatory Filings • Jan 11, 2016

_________ false

C002��� �� �� ������������� ��"�2PublicX T L BIOPHARMACEUTICALS LTD4313Corporation no: 520039470Stock Exchange/Market: NASDAQ CM1996380HaCharoshet st 5 , Ra'anana 43656 , Israel ,Tel: 09-9557080 , Fax: 09-9519708E.mail address: ir@xtlbio.comReported via MAGNA: 11/01/2016              Time of broadcast: 15:34 15:27:22

Company site:		www.xtlbio.com

Reference: 2016-02-007954

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on submittion of a full protocol for advanced stage clinical trial of hCDR1 for the treatment of systemic lupus erythematosus (SLE) to Yeda Research and Development Company Ltd. (Yeda).
XTLB_6K_Yeda_Milestone_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Date of revision of form structure: 31/12/2015
- - -
Name of the Signatory: : Kntor Ronen , Position of Signatory in the reporting corporation: Legal Adviser , Name of Employer Company: .
Abba Hillel Silver Rd Telephone: 03-6133371 , Facsimile: 03-6133372 , E-mail: rkantor@kantor-law.com 2